ly2510924 + carboplatin + etoposide

This is a **combination regimen** of **LY2510924** (a potent, selective cyclic peptide antagonist of C-X-C chemokine receptor type 4, CXCR4), **carboplatin** (a platinum-based chemotherapeutic agent), and **etoposide** (a topoisomerase II inhibitor) developed to treat advanced cancers such as small cell lung cancer (SCLC). LY2510924 inhibits SDF-1α binding to CXCR4, blocking tumor cell migration, proliferation, and prosurvival signaling, and mobilizes hematopoietic stem cells and leukocytes into circulation, which may enhance the effects of chemotherapy. When combined with carboplatin and etoposide, this regimen aims to synergize CXCR4 blockade–induced immune cell trafficking and standard DNA-damaging cytotoxic mechanisms to improve antitumor efficacy[2][1][4][7]. The combination has shown **acceptable toxicity** in early phase studies for advanced SCLC, but did not improve efficacy over standard chemotherapy, suggesting CXCR4 antagonism may have utility in other settings or combinations[2].

Brand names

ly2510924 + carboplatin + etoposide

Other names

ly2510924 + carboplatin + etoposide